Ribociclib plus letrozole achieved a 30.6% overall response rate, with a median progression-free survival of 14.5 months and median overall survival of 44.5 months. The regimen demonstrated durable disease control and a manageable safety profile in recurrent low-grade serous carcinoma.
Study
|
Open-label, single-arm, multicenter phase II study [GOG 3026] |
| Recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum |
| Ribociclib (600 mg orally, days 1-21 of 28-day cycle) + letrozole (n=49)
|
Efficacy
|
ORR: 30.6% (one CR, 14 PR) |
| Median PFS: 14.5 months |
| Median OS: 44.5 months
|
Safety
|
Grade >=3 AEs: neutropenia (47%), small intestinal obstruction (12%), abdominal pain (12%) |
| Treatment discontinuation due to AEs: 4% |
| No dose-limiting toxicities observed
|
J Clin Oncol 2025;44:153-163
http://doi.org/10.1200/JCO-25-01348
Reviewed by Ulas D. Bayraktar, MD on Jan 21, 2026
